Globally, lung cancer is the leading cause of cancer-related deaths. Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancers. Approximately 70% of patients with NSCLC present at locally advanced stages, which are associated with poor survival rates. Although the past decade has witnessed several breakthroughs in the diagnosis, treatment, and management of NSCLC, survival rates remained dismal.
Immunotherapy is rapidly evolving into an effective treatment option for NSCLC. Checkpoint inhibitors (anti-PD-1 and anti-PD-L1 monoclonal antibodies) have shown significant and durable responses in this disease. Combination therapies comprising checkpoint inhibitors and targeted agents are also being evaluated. Given this scenario, it is critical for clinicians to be knowledgeable of the safety/efficacy profile of these novel agents, as well as current data on their timing/sequencing, and patient selection criteria.
In this CME activity, leading experts in NSCLC discuss evidence of the clinical utility of novel immunotherapeutic agents in the treatment of this disease, as well as outcomes from recent clinical trials.